The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Interleukin-6: The Endocrine Cytokine
Abstract
The field of cytokines has expanded tremendously over the last 2 decades. Initially, they were thought to be products of the immune system alone that had immune and hematological functions only. Yet, it has become increasingly apparent that cytokines participate in a neuroendocrine and immune system network, in which both the nervous and endocrine systems participate. Interleukin-6 (IL-6) and, to a lesser extent, tumor necrosis factor α have been shown to have endocrine as well as autocrine and paracrine roles. IL-6, in particular, has drawn much attention in the endocrine field for it is the most “endocrine” of all cytokines. The current issue hosts two articles that further expand our knowledge in the endocrine significance of IL-6. IL-6 is a pleiotropic cytokine with many pathophysiologic roles in humans (1). It is being produced by numerous types of immune or immune accessory cells, such as monocytes, fibroblasts, lymphocytes, and glial cells. It is also produced by nonimmune cells, some typically endocrine. Recently, it has been shown that IL-6 and tumor necrosis factor-α are produced by the adipose tissue (2, 3), suggesting that they may be playing significant roles in lipid metabolism. IL-6 is a hormonally regulated cytokine. Its production is suppressed by glucocorticoids (4) and estrogens (5) and stimulated by catecholamines (6, 7). In turn, it has many endocrine effects. It is one of the major cytokines that stimulate the hypothalamic-pituitary-adrenal axis during inflammatory stress (8); it promotes osteoclastogenesis and participates in the development of osteoporosis associated with estrogen withdrawal (9); it plays a central role in the pathogenesis of the euthyroid sick syndrome (10), most likely by inhibiting 5′-deiodinase that converts T4 to T3 and reverse T3 to diiodothyronine (11). IL-6 was also shown to influence intermediary metabolism (12), to be secreted in a circadian fashion correlating with sleepiness, and to be stimulated by acute sleep deprivation (13). The study by Fernandez-Real et al. (14) in this issue shows that a certain polymorphism in the promoter region of the IL-6 gene results in constitutively higher circulating IL-6 levels, as well as higher circulating triglyceride but not total cholesterol levels, suggesting that changes in the IL-6 gene expression can affect lipid levels through changes in IL-6 production. It has been suggested that IL-6 may cause an increase in circulating lipid levels probably through a decrease in peripheral lipoprotein lipase activity (15). However, the effects of IL-6 on lipid metabolism are far more complex. For example, administration of recombinant human IL-6 was followed by reduction in circulating triglyceride levels in normal volunteers (16). In the same study, total cholesterol as well as apoprotein B levels were decreased after administration of IL-6. Reduction of total cholesterol levels after administration of IL-6 has been observed in nonhuman primates (17) and cancer patients (18), as well. Furthermore, IL-6 levels correlate negatively with cholesterol levels after major surgery (19, 20), in patients undergoing hemodialysis (21), or after myocardial infarction (22). These apparently contradictory data may, indeed, reflect different processes. In the study by Fernandez-Real et al. (14), circulating IL-6 levels correlated positively with circulating triglyceride levels in subjects otherwise normal and in no acute distress. None of these subjects was acutely ill, and the levels of circulating IL-6 were within the normal range. On the other hand, in situations of severe stress—such as major surgery, sepsis, and severe illness—much higher concentrations of circulating IL-6 have been reported that reach 10–1000 times the normal levels. During such situations, activation of the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system is invariably present, besides stimulation of IL-6 production. In addition, the acute phase response is being activated, and this includes suppression of the hepatic production of certain lipoproteins, as well. Thus, it seems that the effects of IL-6 on lipid metabolism depend on the extent of IL-6 induction. It is possible that in the basal, healthy state IL-6 may be influencing triglyceride levels by decreasing lipoprotein lipase activity, without effect on cholesterol concentration. On the other hand, in situations of severe stress, when the acute phase response is activated, along with the nervous and the endocrine systems, the effects on lipid metabolism are far more complex. The decrease in cholesterol acutely after major surgery or a myocardial infarction may actually reflect the negative effect of IL-6 on circulating lipoproteins. Further work is needed to clarify the actions of IL-6 on lipid metabolism in different states of health and disease. The data regarding the correlation between the polymorphism and the free fatty acid (FFA) levels are interesting, but should be considered preli
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
The Pathophysiologic Roles of Interleukin-6 in Human Disease
Papanicolaou, D. A., Wilder, R. L., Manolagas, S. C., & Chrousos, G. P. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-2-199801150-00009 · Cited by 1,146
Self-citationVgontzas, A. N., Papanicolaou, D. A., Bixler, E. O., Kales, A., Tyson, K., & Chrousos, G. P. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.5.3950 · Cited by 974
Self-citationSubcutaneous Adipose Tissue Releases Interleukin-6, But Not Tumor Necrosis Factor- , in Vivo
Mohamed-Ali, V. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.12.4196 · Cited by 717
Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans.
Mastorakos, G., Chrousos, G. P., & Weber, J. S. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.77.6.8263159 · Cited by 591
Circadian Interleukin-6 Secretion and Quantity and Depth of Sleep
Vgontzas, A. N., Papanicolaou, D. A., Bixler, E. O., Lotsikas, A., Zachman, K., Kales, A., Prolo, P., Wong, M.-L., Licinio, J., Gold, P. W., et al. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.8.5894 · Cited by 516
Self-citationBoelen, A., Maas, M. A., Lowik, C. W., Platvoet, M. C., & Wiersinga, W. M. (1996) · Endocrinology · doi:10.1210/endo.137.12.8940342 · Cited by 108
Torpy, D. J., Tsigos, C., Lotsikas, A. J., Defensor, R., Chrousos, G. P., & Papanicolaou, D. A. (1998) · Metabolism · doi:10.1016/s0026-0495(98)90338-9 · Cited by 95
Self-citation
Cited by
Obesity and inflammation: the linking mechanism and the complications
Ellulu, M. S., Patimah, I., Khaza’ai, H., Rahmat, A., & Abed, Y. (2017) · Archives of Medical Science · doi:10.5114/aoms.2016.58928 · Cited by 1,982
Stenvinkel, P., Ketteler, M., Johnson, R. J., Lindholm, B., Pecoits-Filho, R., Riella, M., Heimbürger, O., Cederholm, T., & Girndt, M. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00200.x · Cited by 932
Insulin Resistance and Chronic Cardiovascular Inflammatory Syndrome
Fernández-Real, J. M., & Ricart, W. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0010 · Cited by 886
Goldberg, R. B. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2534 · Cited by 644
Fernandez-Real, J.-M., Vayreda, M., Richart, C., Gutierrez, C., Broch, M., Vendrell, J., & Ricart, W. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.3.7305 · Cited by 567
Metadata
- Authors
- Papanicolaou, D. A.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2000-03-01
- Volume
- 85
- Issue
- 3
- Pages
- 1331-1333
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2053765850
- Cited by
- 158
- References
- 8
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interleukin-6: The Endocrine Cytokine. https://app.cochat.ai/papers/10.1210/jc.85.3.1331
- The paper
- Papanicolaou, D. A. (2000). Interleukin-6: The Endocrine Cytokine. Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.85.3.1331
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.